A Review of Emerging Biomarkers for Immune Checkpoint Inhibitors in Tumors of the Gastrointestinal Tract

05 February 2022 : Review article

Xuqiang Liao^1AE, Gao Li^1B, Renzhong Cai^1AF, Ru Chen^1AG*

DOI: 10.12659/MSM.935348

Med Sci Monit 2022; 28:e935348

Background Pan-Tumor Biomarkers Colon Cancer Stomach Cancer Esophageal Cancer Liver Cancer Pancreas Cancer Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 2 Controversial findings of the predictive value of PD-L1 expression for the efficacy of immunotherapy in gastrointestinal tumors.

Biomarker	Tumor	Study	Drug	Correlation
PD-L1 expression in tumor cells	HCC	CheckMate-040 []²²	Nivolumab	No significant correlation
PD-L1 expression in tumor cells	GC	Attraction-2 []¹⁵	Nivolumab	No significant correlation
PD-L1 expression in tumor cells, lymphocytes, and macrophages	GC/GEJC	KEYNOTE-059 []¹⁶	Pembrolizumab	Significantly relevant
PD-L1 expression in tumor cells, lymphocytes, and macrophages	HCC	KEYNOTE-224 []²⁹	Pembrolizumab	Significantly relevant
PD-L1 expression in tumor cells, lymphocytes, and macrophages	EC	KEYNOTE-180 []³⁰	Pembrolizumab	No significant correlation
HCC – hepatocellular carcinoma; GC or GEJC – gastric or gastroesophageal junction cancer; EC – esophageal cancer; PD-L1 – programmed death-1 ligand-1.

Back to the Article